India Set To Become Hub For Clinical Trials ( India is fast emerging as an attractive...)

India Set To Become Hub For Clinical Trials

India is fast emerging as an attractive destination for conducting global clinical trials due to availability of vast pool of patients and also well trained medical professionals and sophisticated technological infrastructure. //

The clinical research outsourcing market in India was valued at Rs 3.1 billion in 2005 and is expected to grow to Rs 13.2 billion by 2010. Most of the US and European nations are outsourcing clinical trials to India, says Mahesh Sawant of Healthcare Practice, Frost & Sullivan, a market research company.

'A huge patient population, genetically distinct groups, speciality hospitals with state-of-the-art facilities, nearly 700,000 hospital beds and 221 medical colleges, skilled Engligh speaking investigators are India's trump cards,' says Sawant.

'The entire world is watching the growth and performance of India in this segment of business. There are positive signals and reports which justify the trends for pharmaceutical sponsors to look seriously at India for carrying forward their drug development intitiatives,' notes Dr Umakanta Sahoo, Head, India Operations, Chiltern International, a clinical research organisation.

A CII study predicts that the clinical trials market will grow to 200 million dollars by 2007 and anywhere between 500 million and one billion dollars by 2010, Sahoo says.

Source:PTI News

Page: 1
Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. AIDS Disaster in India is Imminent
3. Indian Prime Minister has successful Knee Replacement Surgery
4. International community warns India on HIV situation
5. India takes on foot-and-mouth disease by vaccinating animals
6. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
7. India to benefit from pharma companies move
8. Healthcare sector is now a multi billion-dollar industry in India
9. The World Bank funds private Hospital in India
10. Parke-Davis (India) runs into rough weather – Court orders attachment of asset
11. Indian Doctor granted US patent on organ regeneration

Post Your Comments:

(Date:5/23/2012)... acne, and they deal with the embarrassing skin ... Accutane or Roaccutane. Now, however, research from Tel ... cause eye infections such as conjunctivitis (pink eye) ... of TAU,s School of Public Health at the ... a connection between acne and eye infections, but ...

(Date:5/23/2012)... Blame it on your genes? Researchers from The Miriam ... variations in certain "obesity genes" tend to eat more meals ... the same types of high fat, sugary foods. , Their ... Nutrition and appearing in the June issue, reveals certain ... been previously linked to obesity may play a role ...

(Date:5/23/2012)... in Sweden shows that phthalates from PVC flooring materials ... suspected to cause asthma and allergies, as well as ... children can ingest these softening agents with food but ... are a group of chemical compounds that occur in ... goods such as toys, cleaning solvents, packaging, etc. Phthalates ...

(Date:5/23/2012)... -- The use of physical restraints in nursing ... that includes more training and supportive materials for ... German study. Despite legal regulations and evidence ... bed rails and belts still are frequently used ... the rate of physical-restraint use in U.S. nursing ...

(Date:5/23/2012)... Researchers in the United Kingdom have determined that ... properties, can be an effective treatment option for ... life-threatening complication that occurs in the majority of ... the leading cause of mortality after the first ... the body repeatedly rejects the transplanted lung tissue. ...

Breaking Medicine News(10 mins):Health News:Common acne medication doubles risk of eye infection 2 Health News:'Obesity genes' may influence food choices, eating patterns 2 Health News:Phthalates in PVC floors taken up by the body in infants 2 Health News:Study Offers Ways to Decrease Use of Restraints at Nursing Homes 2 Health News:Study shows antibiotic improves respiratory function in lung transplant patients 2

[0] Common acne medication doubles risk of eye infection [0] 'Obesity genes' may influence food choices, eating patterns [0] Phthalates in PVC floors taken up by the body in infants [0] Study Offers Ways to Decrease Use of Restraints at Nursing Homes [0] Study shows antibiotic improves respiratory function in lung transplant patients

... Year-to-date, NANJING, China, Nov. 5 /Xinhua-PRNewswire-FirstCall/ -- ... manufacturer and supplier of,branded generic pharmaceuticals and manufacturer ... today reported unaudited,financial results for the quarter ended ... -- Total revenue increased to RMB323.4 million ...

... Genelabs,Technologies, Inc. (Nasdaq: GNLB ) announced today ... at the Acumen BioFin Rodman & Renshaw,9th Annual ... am,Eastern Time. The webcast can be accessed through ... at http://www.Genelabs.com . About Genelabs Technologies ...

... Nov. 5 Cardinal Health, a,global provider of ... of health care, announced that effective today, Mark ... officer of the company,s,Healthcare Supply Chain Services (HSCS) ... W. Henderson, 42, will assume the,additional role of ...

... Data Indicate New HspE7 Promotes More Potent ... 5 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX:NVN) today ... the 24th International Papillomavirus,conference, the largest annual ... the field of human papillomavirus (HPV), taking ...

... FRANCISCO, Calif., Nov. 5 OTN, a leading,physician ... of products,and services to the community physician market, ... community-based practices, today,announced that Oncology Physician Resource (OPR) ... for another year. Under the extended,agreement, which is ...

... Nov. 5 HealthCoach,( http://www.healthcoach.net ) is pleased ... as Vice President of Consulting. James will drive ... the,adoption of healthy lifestyle habits for both by ... the overall development of,the HealthCoach corporate service offerings. ...

Simcere Pharmaceutical Group Reports Third Quarter 2007 Results Genelabs Technologies to Present at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference Cardinal Health Announces Sector Management Change Nventa presents HspE7 data at international HPV conference Oncology Physician Resource (OPR) Extends Agreement With OTN and Onmark as Oncology Services Partner HealthCoach Welcomes James Herrera as Vice President of Consulting

(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...

(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012 Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...

(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...

Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2 Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3 Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2 Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4 ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1 ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4

[0] Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting [0] Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream [0] Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.

... 15, 2007 - Synthetic Blood,International, Inc. (OTCBB:SYBD) ... of its Phase IIa study with Oxycyte(TM) ... with preliminary,study results announced in December 2006, ... increasing patients' oxygen,tension levels compared with baseline ...

... Treatment with ISIS 301012 produced at least ... to,maximally-tolerated lipid-lowering therapies, CARLSBAD, Calif., May 17, ... results from its ongoing,Phase 2 clinical trial ... hypercholesterolemia (HoFH), initial results of which were,presented ...

Other Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2 Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5

Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients

... NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2) is ... injury, predicting acute renal failure with a ... increased, especially in urine, as early as ... NGAL an ideal diagnostic marker for acute ...

... 253 is an assayed quality control material ... hemoglobin and hemoglobin fractions on CO-Oximeter instrumentation. ... a control that parallels the human physiologic ... 253 is available in three (3) levels ...

... QC 233 is an ... for monitoring the measurements of ... on CO-Oximeter instrumentation. It is ... for monitoring analyzer performance at ...

... 623 is an assayed quality control material for ... in four (4) levels for monitoring analyzer performance ... may be used on multiple test analyzers (such ... Radiometer 600). QC623 is also for use on ...

Medicine Products:

NGAL Rapid ELISA Kit QC 253 Full Range CO-Oximeter Control QC 233 CO-Oximeter Control QC 623 Blood Gas, Electrolyte Control

( India is fast emerging as an attractive...)India Set To Become Hub For Clinical Trials,Health